Food and Drug Administration

Oncologic Drugs Advisory Committee

September 11, 2001


BLA 125019, Zevalin™ (ibritumomab tiuxetan), IDEC Pharmaceuticals Corporation
- indicated for the treatment of patients with relapsed or refractory low grade, follicular or CD20+ transformed B cell Non-Hodgkins lymphoma (NHL) and rituximab refractory follicular NHL

FDA Presentation  ppt   htm


The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Ibritumomab Tiuxetan (Zevalin™) Radioimmunotherapy of Non-Hodgkin's Lymphoma, IDEC Pharmaceuticals Corporation   ppt   htm

Measuring Normal Tissue Effects of Radionuclide Therapy, Ruby Meredith, MD, PhD, University of Alabama at Birmingham   ppt   htm

BLA #125019 Zevalin™ kit, Philippe Bishop, MD, FDA   ppt   htm